Come up with a name for your new list and we'll add to it:
Isarna Therapeutics raised a round of funding on April 29, 2004. Investors include
Global Asset Fund.
Isarna Therapeutics has a commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. The company is advancing a unique pipeline of novel oligonucleo…